Inhibikase Therapeutics, Inc. Earnings Per Share Diluted

Quick Answer

Inhibikase Therapeutics, Inc. reported Earnings Per Share Diluted of $0.49 (loss) per share for the year ending 2025.

  • Inhibikase Therapeutics, Inc. showed an increase of +57.8% in Earnings Per Share Diluted from 2024 to 2025.
  • This data is from Inhibikase Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
  • XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2021 to 2025), Inhibikase Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 39.5%.
  • Historical annual values: Fiscal year 2025: $0.49 (loss) per share | Fiscal year 2024: $1.16 (loss) per share | Fiscal year 2023: $3.16 (loss) per share | Fiscal year 2022: $4.28 (loss) per share | Fiscal year 2021: $0.81 (loss) per share.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: